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HIV-1 subtype A infection predominates in Russia; however, little experience of response to maraviroc in this subtype exists and
population genotyping in this setting requires further exploration. One hundred and twenty-one treatment-naı ¨ve HIV-1-infected
individuals from seven centres in Russia were screened using V3 loop population genotyping with a false-positive rate of 10%
(geno2pheno); 75% of patients were confirmed to have CCR5 (R5)-tropic HIV-1, 21% of patients had non-R5 HIV-1, and 4% of
tests were non-reportable. Seventy-seven patients met the inclusion criteria and were treated with maraviroc 300 mg twice daily
(BID) in combination with lamivudine/zidovudine. Virologic and immunologic responses were assessed in this 24-week planned
interim analysis. Fifty-one male (66.2%) and 26 (33.8%) female patients were enrolled. In total, 76.3% of patients had subtype A
infection, and 28.6% were co-infected with hepatitis C virus. At baseline, the mean (9 standard deviation [SD]) CD4 count was
4049122 cells/mm
3, and the mean viral load was 4.7790.74 log10 copies/mL, with 38% of patients having viral loads
]100,000 copies/mL. At Week 24, 80.5% of patients had viral loads B50 copies/mL and the mean (9SD) CD4 cell count was
4119124 cells/mm
3. No treatment-emergent adverse events were attributed to maraviroc, and three patients experienced
Grade 4 anaemia associated with lamivudine/zidovudine. Seven patients discontinued from the study, but only one of these
discontinuations was due to an insufficient clinical response. Two patients had 3TC resistance at the time of discontinuation.
Virologic responses to a maraviroc-based regimen in patients infected with R5-tropic HIV-1 subtype A, determined using
population genotyping, were confirmed.
Published 11 November 2012
Copyright: – 2012 Portsmouth S et al; licensee International AIDS Society. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection
Portsmouth S et al. Journal of the International AIDS Society 2012, 15(Suppl 4):18261
http://www.jiasociety.org/index.php/jias/article/view/18261 | http://dx.doi.org/10.7448/IAS.15.6.18261
1